Chimerix's trial treating pediatric brain tumors has a 'relatively high' chance of successProactive Investors • 05/25/23
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 05/04/23
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023GlobeNewsWire • 04/27/23
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual MeetingGlobeNewsWire • 04/18/23
Chimerix (CMRX) Loses -24.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 03/29/23
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational UpdateGlobeNewsWire • 03/02/23
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational UpdateGlobeNewsWire • 12/08/22
Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 11/29/22